Key result
SMTP-7 reduces cerebral infarction area ~79% vs control with less hemorrhagic transformation than t-PA.
Why the study?
Does SMTP-7 improve outcomes in a mouse model of embolic cerebral infarction compared to vehicle or t-PA?
Does SMTP-7 improve outcomes in a mouse model of embolic cerebral infarction compared to vehicle or t-PA?
SMTP-7 demonstrated potential as a novel thrombolytic agent with anti-inflammatory effects, a wider therapeutic time window, and lower hemorrhagic risk compared to t-PA in a mouse model of cerebral infarction.
Answers are grounded in this paper and cite their sources.
Should not yet alter clinical thrombolysis; hypothesis-generating for SMTP-7 with wider window and lower hemorrhage risk in stroke.
Tissue plasminogen activator (t-PA) has a short therapeutic time window for administration (3 h) and carries a risk of promoting intracerebral hemorrhage. The aim of the present study was to investigate a therapeutic time window and frequency of hemorrhagic region by treatment with Stachybotrys microspora triprenyl phenol-7 (SMTP-7). Thrombotic occlusion was induced by transfer of acetic acid-induced thrombus at the right common carotid artery into the brain of mice. Infarction area, neurological score, edema percentage, and regional cerebral blood flow (CBF) were determined as the index of the efficacy of SMTP-7. In order to evaluate the mechanism of SMTP-7, plasmin activities and the expressions of interleukin (IL)-1beta, tumor necrosis factor-alpha (TNF-alpha), and IL-6 mRNA were examined. SMTP-7 (0.1, 1, 10 mg/kg) dose dependently reduced infarction area, neurological score, and edema percentage. Additionally, its therapeutic time window was longer than that of t-PA, a high-molecular-weight compound. In addition, little hemorrhagic region was induced by treatment with SMTP-7. SMTP-7 showed plasmin activity in vivo and caused a decreased CBF to recover. Furthermore, the expressions of inflammatory cytokine mRNA (IL-1beta, TNF-alpha, IL-6) were increased by t-PA treatment 3 h after ischemia but were not induced by SMTP-7 treatment. These results indicate that SMTP-7 shows potential thrombolytic and anti-inflammatory effects as well as a wide therapeutic time window and little hemorrhagic region compared with that of t-PA. Therefore, this novel low-molecular-weight compound may represent a novel approach for the treatment of cerebral infarction.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2010) studied Embolic cerebral infarction. SMTP-7 vs. Vehicle and t-PA was evaluated on Infarction area (78.9% reduction, p=<0.01). SMTP-7 at /kg reduced cerebral infarction area by 78.9% compared to control, while exhibiting a wider therapeutic time window and less hemorrhagic transformation than t-PA.
Synapse has enriched 10 related papers. Consider them for comparative context: